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Abstract
Background: Amniotic fluid embolism (AFE) is a rare but severe complication of pregnancy. A recent systematic
review highlighted apparent differences in the incidence, with studies estimating the incidence of AFE to be more
than three times higher in North America than Europe. The aim of this study was to examine population-based
regional or national data from five high-resource countries in order to investigate incidence, risk factors and
outcomes of AFE and to investigate whether any variation identified could be ascribed to methodological
differences between the studies.
Methods: We reviewed available data sources on the incidence of AFE in Australia, Canada, the Netherlands, the
United Kingdom and the USA. Where information was available, the risk factors and outcomes of AFE were examined.
Results: The reported incidence of AFE ranged from 1.9 cases per 100 000 maternities (UK) to 6.1 per 100 000
maternities (Australia). There was a clear distinction between rates estimated using different methodologies. The
lowest estimated incidence rates were obtained through validated case identification (range 1.9-2.5 cases per 100
000 maternities); rates obtained from retrospective analysis of population discharge databases were significantly
higher (range 5.5-6.1 per 100 000 admissions with delivery diagnosis). Older maternal age and induction of labour
were consistently associated with AFE.
Conclusions: Recommendation 1: Comparisons of AFE incidence estimates should be restricted to studies using similar
methodology. The recommended approaches would be either population-based database studies using additional
criteria to exclude false positive cases, or tailored data collection using existing specific population-based systems.
Recommendation 2: Comparisons of AFE incidence between and within countries would be facilitated by
development of an agreed case definition and an agreed set of criteria to minimise inclusion of false positive cases
for database studies.
Recommendation 3: Groups conducting detailed population-based studies on AFE should develop an agreed
strategy to allow combined analysis of data obtained using consistent methodologies in order to identify
potentially modifiable risk factors.
Recommendation 4: Future specific studies on AFE should aim to collect information on management and longer-
term outcomes for both mothers and infants in order to guide best practice, counselling and service planning.
Background
Amniotic fluid embolism (AFE) is a rare but severe
complication of pregnancy. The rarity of the condition
and the fact that AFE is a diagnosis of exclusion, make
it particularly challenging to study and therefore difficult
to obtain reliable information about incidence, risk
factors, management and outcomes. Centre-based stu-
dies, because of the small population they cover, or
because of the long historical period which has to be
studied in order to identify a sufficient number of cases,
rarely generate robust and reproducible results which
can be generalised to today’s obstetric populations. As
AFE is infrequent, the most robust studies of the condi-
tion are population-based studies, ideally incorporating
large numbers of pregnant women in order to have suf-
ficient statistical power to generate stable incidence
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the independent risk associated with each. Multinational
studies can enhance further the robustness, timeliness
and hence utility of study results.
A recent systematic review highlighted apparent differ-
ences in the incidence of AFE in different studies [1],
with estimates being more than three times higher in
North America than Europe [2-6]. The aim of this study
was to examine population-based regional or national
data within five high resource countries in order to
investigate incidence, risk factors and outcomes of AFE
and to investigate whether any variation identified could
be ascribed to methodological differences between the
studies.
Methods
We reviewed available data sources on the incidence of
AFE in Australia, Canada, the Netherlands, the United
Kingdom and the USA. Where information was avail-
able, data on the risk factors and outcomes of AFE were
also reviewed. Because of variations in definitions of
AFE used between countries and between data sources,
we did not restrict our analysis to AFE defined using
any one particular classification. The definitions and
codes used to identify cases in each country are shown
in table 1. Maternal death was defined throughout as
death of a woman while pregnant or within 42 days of
the termination of pregnancy.
Data sources
Australia
Fatal cases were identified through four published trien-
nial Maternal Deaths in Australia reports [7-10]. The
Maternal Deaths in Australia reports are a compilation
of confidential death reviews conducted at the jurisdic-
tional level. Information for incident cases (fatal and
non-fatal) was obtained from the National Hospital
Morbidity Database (NHMD) [11] an administrative col-
lection of hospital separations for the years 1994-2005.
The NHMD is a collection of confidential summary
Table 1 Definitions and codes used for AFE
Country ICD-9
coding
ICD-10
Coding
Other definition used
Australia (NSW) N/A O88.1 1) if not fatal, the hospital record had to include a diagnosis of one or more of cardiac arrest,
hypotension syndrome, respiratory distress, coagulation defects, coma and/or seizure, and an absence of
other medical conditions or potential explanations of the symptoms and signs [1] and 2) where death
was the outcome, AFE had to be listed as the cause of death.
Australia
(Victoria)
N/A O88.1
Australia
(national data)
673.1 O88.1 Review of maternal death by expert committee in conjunction with a cause of death of amniotic fluid
embolism
Canada 673.1 O88.1
Netherlands N/A N/A - Reported as maternal mortality or severe maternal morbidity with AFE as diagnosis or in differential
diagnosis
- One or more of the following severe enough to require medical treatment:
Hypotension (and/or cardiac arrest)
Respiratory distress
Disseminated intravascular coagulation
Coma and/or seizures
- Absence of any other clear medical explanation for the clinical course.
United Kingdom N/A N/A In the absence of any other clear cause
EITHER
Acute maternal collapse with one or more of the following features:
Acute fetal compromise
Cardiac arrest
Cardiac rhythm problems
Coagulopathy
Hypotension
Maternal hemorrhage
Premonitory symptoms e.g. restlessness, numbness, agitation, tingling
Seizure
Shortness of breath
Excluding: women with maternal hemorrhage as the first presenting feature, in whom there was no
evidence of early coagulopathy or cardio-respiratory compromise
OR
Women in whom the diagnosis was made at post-mortem examination with the finding of fetal
squames or hair in the lungs
USA 673.1 N/A If not fatal, ICD-9CM code of 673.1.
For fatal cases, coding indicating AFE as cause of death or major contributing factor to the death
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private hospitals in Australia. The NHMD is based on
data from the state and territory health authorities and
is compiled nationally by the Australian Institute of
Health and Welfare. Diagnoses and procedures were
coded according to the International Classification of
Diseases (ICD), tenth revision, Australian Modification
(ICD10 AM) (ICD-9 prior to 1999). Records were
selected based on a diagnosis of AFE using ICD9 Clini-
cal Modification (CM) code of 637.10-637.14 with a
birth code (V27.0-V27.2) or a code for care immediately
following delivery (V24.0) or postpartum examination
and care (V24.3). The ICD9 coding system includes a
fifth digit (0-4) for obstetric codes that indicates the
timing of the diagnosis of the condition relative to the
birth; and for ICD-10AM O88.1 with Z37.0-Z37.9 used
to flag a birth episode and Z39.01 to flag an immediate
postpartum episode. Data were available for all jurisdic-
tions in Australia, accounting for 100% of all women
giving birth in hospital.
In New South Wales (NSW) data on incident cases
(fatal and non-fatal) were obtained from the Admitted
Patient Data Collection (APDC), a census of all hospital
discharges from public and private hospitals, and linked
to the Midwives Data Collection (MDC), a legislated
surveillance system of all births in NSW completed by
attending midwives and doctors [12]. Diagnoses and
procedures obtained from the medical records for each
hospitalisation are ICD-10-AM and the affiliated Austra-
lian Classification of Health Interventions. Data for
2001-2007 inclusive were examined. A previous valida-
tion study encountered only one case of AFE, and this
was correctly coded [13].
D a t af o rV i c t o r i aw e r ed e r i v e df r o mt h eV i c t o r i a n
Perinatal Data Collection (VPDC) which is completed
by the birth attendant (usually the midwife) for each
birth [14]. Diagnoses are coded according to ICD-10-
AM (VPDC modification). Case validation was con-
ducted through medical review of the Victorian Perina-
tal Data files of all cases identified. AFE diagnosis was
confirmed if surviving mothers required admission to
ICU, and/or had major blood transfusion of > 2 units,
or pathology reports from autopsy were compatible with
AFE.
Canada
As previously reported [4], information on incident
cases (fatal and non-fatal) for Canada was based on all
hospital deliveries as documented in the Discharge
Abstract Database of the Canadian Institute for Health
Information from 1991 to 2002, which records all deliv-
eries in Canada with the exception of those in Quebec,
Manitoba and Nova Scotia (thus approximately 70% of
deliveries). All medical diagnoses were coded using the
International Classification of Diseases (ICD-9 up to
2000, and a combination of ICD-9 and ICD-10 from
2001-2002), while procedures were coded using the
Canadian Classification of Diagnostic, Therapeutic and
Surgical Procedures (CCP) for 1991-2001 and the Cana-
dian Classification of Interventions (CCI) for 2001-2.
The Netherlands
Fatal cases were identified from the Dutch Confidential
enquiries into the causes of maternal mortality between
1983-1992 and 1993-2005 [15]. Incident cases (fatal and
non-fatal) were identified through the LEMMoN study
of severe maternal morbidity between 2004 and 2006
[16]. In each hospital in the Netherlands with a consul-
tant-led maternity unit, a nominated reporting clinician
notified cases on a monthly basis using a standard web-
based reporting form. For both fatal and incident cases,
specific information on diagnosis, characteristics of the
case and management was collected using a standar-
dised form in addition to copies of selected anonymised
parts of the case record. These data were used for sub-
sequent case validation by the committee.
United Kingdom
Fatal cases were identified through the United Kingdom
(UK) confidential enquiries into maternal deaths
between 2003 and 2008 [17,18].
UK data on incident cases of AFE (fatal and non-fatal)
were obtained through the UK Obstetric Surveillance
System (UKOSS) between February 2005 and January
2010 [3]. In each hospital in the UK with a consultant-
led maternity unit, nominated reporting clinicians noti-
fied cases using a monthly reporting card. In response
to a report of a case, clinicians were asked to complete
a data collection form confirming the case definition,
characteristics of the case, management and outcomes.
United States
Fatal cases were identified through the Pregnancy Mor-
tality Surveillance System (PMSS) in the Division of
Reproductive Health at the Centers for Disease Control
and Prevention (CDC) [19]. Since 1986, PMSS has used
matched vital records to identify deaths caused by preg-
nancy complications occurring during or within one
year of the end of pregnancy.
Non-fatal and fatal incident cases were obtained from
the Nationwide Inpatient Sample (NIS) for 1999-2008.
The NIS is part of the Agency for Healthcare Research
and Quality’s Healthcare Cost and Utilization Project.
The NIS [20] contains data on 5 to 8 million hospital
stays and, with appropriate weighting, generates a
nationally representative sample of inpatient hospital
admissions. The database contains up to 15 diagnosis
fields and 15 procedure fields; diagnoses and procedures
are coded at the hospital at discharge using the ICD-9-
CM. Except for age, the NIS does not collect individual
demographic information nor does it report obstetrical
characteristics for individual pregnancies except those
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pitalisations were identified using a previously published
algorithm based on ICD-9-CM diagnosis and procedure
codes and diagnosis-related group (DRG) codes [21].
Statistical analyses
Incidence rates for AFE with 95% confidence intervals
were calculated using as a denominator the number
of maternities, deliveries or live births recorded
regionally or nationally during each study period.
Putative risk factors, identified from factors previously
reported in the literature (maternal age, parity, smok-
ing status, race/ethnicity, diabetes, multiple preg-
nancy, previous caesarean delivery, hypertensive
disorders, placenta praevia, placental abruption, pre-
sentation at delivery, chorioamnionitis, polyhydram-
nios, induction of labour, mode of delivery, manual
removal of placenta, macrosomia, gestational age at
delivery) [1-4,22], were examined using univariable or
full multivariable logistic regression analysis where
possible and results presented as odds ratios (ORs)
with 95% confidence intervals. Where individual level
comparison group data were not available, associa-
tions were examined by comparing data on the pro-
portion of cases with a particular risk factor with data
on the proportion of the population of women giving
birth with the same risk factor using risk ratios with
95% confidence intervals.
Ethics Committee Approval
The UK AFE study was approved by the London Multi-
centre Research Ethics Committee (ref 04/MRE02/46)
and the linkage and use of New South Wales data was
approved by the NSW Population and Health Services
Research Ethics Committee (2006-06-011). The Dutch
LEMMoN study was centrally approved by the medical
ethics committee of the Leiden University Medical Cen-
tre (ref P04-020). No other permissions were required
for use of the data presented.
Results
Incidence
The reported incidence of AFE ranged from 1.9 cases per
100 000 maternities (UK) to 6.1 per 100 000 maternities
(Australia) (Table 2). There was a clear distinction
between rates estimated using different methodologies.
The lowest estimated incidence rates were obtained
through validated prospective case identification (range
1.9-2.5 cases per 100 000 maternities); rates obtained
from retrospective analysis of population discharge data-
bases were significantly higher (range 5.5-6.1 per 100 000
admissions with delivery diagnosis), with an intermediate
estimated incidence obtained from analysis of a regional
discharge database in which additional required criteria
(at least one of the cardinal symptoms with no other
potential explanation) were used to exclude false positive
cases (3.3 cases per 100 000 maternities). When the latter
database was used without the additional selection cri-
teria, the estimated incidence was 6.3/100,000.
Mortality and case fatality
Mortality ratios ranged from 0.4 per 100 000 live births
in the Netherlands from 1993-2005 to 1.3 per 100 000
live births in the United States in 1997-2001 and 1.1 in
Australia excluding Victoria in 1994-2005. Case-fatality
rates ranged from 11 to 43%. There were no clear differ-
ences in estimates of maternal mortality due to AFE or
case fatality rates due to AFE using any different metho-
dology, noting the limited power to detect differences
due to small numbers of fatal cases (Tables 3 and 4).
T h es t u d i e sw i t ht h eh i g h e s tc a s ef a t a l i t yr a t e s( N S W
and Victoria) were conducted using case validation.
Note, however, the wide confidence intervals surround-
ing all case fatality estimates due to the rarity of the
condition and the small numbers involved.
Associated factors
The only factors consistently associated with AFE across
all five countries were induction of labour and maternal
Table 2 Incidence
Country Years Cases AFE rate 95% CI
Validated case identification
UK 2005-2010 72 1.9/100 000 maternities (deliveries ≥ 24 wks) 1.5-2.4
Netherlands 2004-2006 9 2.5/100 000 maternities
(deliveries ≥ 24 wks)
1.3-4.8
Victoria 2000-2008 14 2.4/100 000 maternities (deliveries > 20 wks,400 g) 1.3-4.0
Population Database with additional criteria to exclude false positive cases
Australia (NSW) 2001-2007 20 3.3/100 000 maternities (deliveries > 20 wks, 400 g) 1.9-4.7
Population Database without additional criteria
US [NIS] 1999-2008 2226 5.5/100 000 admissions with delivery diagnosis 5.5-5.5
Canada 1991-2002 180 6.0/100 000 deliveries (> 20 wks 400 g) 5.3-7.1
Australia 1994-2005 185 6.1/100 000 admission a with a delivery diagnosis (deliveries > 20 wks, 400 g) 5.2-6.9
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the association was not statistically significant. The asso-
ciation with age was not statistically significant in the
Dutch data, this could be due to limited study power
since all cases occurred in women who were aged 29
years or greater (Table 5). The methods of induction
investigated varied. UK and Dutch data show a signifi-
cant association between AFE and induction of labour
(all methods); in the Canadian population, an associa-
tion was observed with medical induction of labour,
whereas in New South Wales there was only a statisti-
cally significant association with medical induction using
vaginal prostaglandin. In the US study, induction of
labour (all methods) was associated with raised odds
(aOR 1.5), but this was not statistically significant.
Where data were available, there were increased odds of
AFE associated with placenta praevia and placental
abruption. For all of the other factors examined (Tables
5, 6, 7, 8), the associations varied in the direction of
effect and statistical significance, which may reflect
small numbers and consequent lack of study power.
Other associations were noted with mode of delivery:
forceps/vacuum and caesarean section, although these
are challenging to interpret since information on the
timing of delivery in relation to the AFE was not avail-
able for all of the data sources. In the UK data, where
timing of the event and delivery was available, there was
a statistically significant association noted with caesar-
ean section delivery when the AFE occurred after deliv-
ery. There was no association with forceps or vacuum
delivery, although the small number of women with
AFE who had operative vaginal deliveries means there is
limited statistical power to examine this association. Of
note, eclampsia, a condition which may form one of the
differential diagnoses for AFE, was strongly associated
with AFE in the Canadian and US studies which did not
use additional criteria to exclude false positive cases.
Very limited data were available on factors associated
with fatality (Table 9); there were no factors consistently
associated with fatality across all of the countries.
Outcomes
For the majority of sources used, there was very limited
information on maternal outcomes other than death.
Cerebral injury was noted in 6% of women with AFE in
the UK, and cerebral infarction occurred in 20% of
women with AFE in New South Wales. Data were simi-
larly limited on fetal and infant outcomes. Eight of 21
infants (38%) born to mothers with AFE in the Nether-
lands were stillborn or died in the neonatal period; the
figure was 5 of 75 infants (7%) in the UK and 6 of 19
(32%) in NSW.
Discussion
Incidence of AFE
This analysis demonstrates differences in the reported
incidence of AFE in high-resource countries; the
reported incidences vary according to the study metho-
dology. Incidence estimates generated from analysis of
population databases without additional criteria to
exclude false positive cases produce more than double
the estimates generated from analyses using specific
Table 3 AFE Mortality ratios
Country Years Cases Mortality 95%
CI
Validated case identification
UK 2003-
2005
17 0.8 per 100 000
maternities
0.5-1.3
UK 2006-
2008
13 0.6 per 100 000
maternities
0.3-1.0
Netherlands 1983-
1992
2 0.1 per 100 000 live
births
0.0-0.4
Netherlands 1993-
2005
11 0.4 per 100 000 live
births
0.2-0.8
Australia
(national)
1994-
2005
33 1.1 per 100 000
maternities
0.7-1.4
Australia
(Victoria)
2000-
2008
6 1.0 per 100 000
maternities
0.4-2.2
Population Database with additional criteria to exclude false
positive cases
Australia (NSW) 2001-
2007
6 1.2 per 100 000
maternities
0.3-2.0
Population Database without additional criteria
US (PMSS) 1991-
1996
237 0.9 per 100 000 live
births
*
US (PMSS) 1997-
2001
256 1.3 per 100 000 live
birth
*
US (PMSS) 2002-
2005
171 1.0 per 100 000 live
births
*
Canada 1991-
2002
24 0.8 per 100 000
deliveries
0.5-1.2
*Based on data on all births therefore no confidence intervals quoted
Table 4 AFE case fatality
Country Years Case fatality rate 95% CI
Validated case identification
UK 2005-2010 19% 11-30%
Netherlands 2004-2006 11% 3-45%
Australia (Victoria) 2000-2008 43% 18-71%
Population Databases with additional criteria to exclude false
positive cases
Australia (NSW) 2001-2007 35% 15-59%
Population Databases without additional criteria
US
[PMSS+NIS]
1993-1998 21% 18-22%
US
[PMSS+NIS]
1999-2005 18% 17-21%
Canada 1991-2002 13% 8-19%
Australia (national, NHMD) 1994-2005 14% 9-19%
Knight et al. BMC Pregnancy and Childbirth 2012, 12:7
http://www.biomedcentral.com/1471-2393/12/7
Page 5 of 11validated case identification; an estimate from a popula-
tion database analysis with additional criteria to exclude
false positive cases was compatible with the estimates
from the validated case identification studies. Compari-
son of the AFE incidence using a population database
with and without criteria to exclude false positive cases
also found this pattern, with the estimated incidence
from the unselected population database double that
when the additional criteria were used. This suggests
that the noted European-North American differences in
i n c i d e n c e[ 1 ]a r ea l s ol i k e l yt ob ee x p l a i n e db yt h ed i f -
ferences in methodology used, and may not represent a
true difference in incidence between the countries.
It is difficult to determine which of these estimates is
likely to represent a value closest to the “true” incidence
of AFE. The apparently lower case fatality amongst
Table 5 Maternal factors associated with amniotic fluid embolism
Australia (NSW) Canada Netherlands UK US
Maternal factors
Age < 20 years * aOR 0.2
(0.1-0.96)
No cases * aOR 0.4 (0.2-0.9)
Age ≥ 35 years RR 4.8 (2.0-12) aOR 1.9
(1.4-2.7)
RR 2.4 (0.7-9.1) aOR
≠ 2.7 (1.4-5.1) aOR 2.2 (1.5-2.1)
Multipara RR 3.7 (0.9-8.1) * RR 6.6 (0.8-52.7) aOR
≠ 0.9 (0.5-1.7) *
Smoked during
pregnancy
RR 1.5 (0.5-4.6) * * aOR
≠ 0.9 (0.4-2.2) *
Socioeconomic status Disadvantaged (lowest
quartile)
RR 1.6 (0.6-4.0)
* * Routine, manual occupation or
unemployed
aOR
≠ 0.5 (0.3-1.0)
*
Race/Ethnicity
(Baseline group white or
native born)
East Asian country of
birth RR 2.4 (0.8-7.2)
* Non-Western
immigrants RR 1.3 (0.3-
6.1)
Black or other ethnic minority
group aOR
≠ 1.2 (0.5-2.6)
African American
aOR 2.4 (1.5-3.6)
Other aOR 2.3 (1.5-
3.6)
Diabetes (pregnancy and
pre-pregnancy)
* aOR 1.5
(0.6-3.8)
* * aOR 2.3 (0.6-9.2)
RR = Relative Risk, aOR = adjusted Odds Ratio
≠ Adjusted for age, parity, smoking status, socioeconomic status, ethnicity, bmi, multiple pregnancy, placenta praevia or abruption, labour induction and
postdates
* No data or no accurate or limited data
Table 6 Pregnancy factors associated with amniotic fluid embolism
Australia (NSW) Canada Netherlands UK US
Pregnancy factors
Multiple pregnancy * OR 2.5 (0.9-6.2) RR 7.1 (0.9-
56.5)
aOR
≠ 5.3 (1.2-
23.0)
*
Previous caesarean RR 1.7 (0.5-6.0) aOR 0.8 (0.5-1.2) * * aOR 0.9 (0.6-1.3)
Hypertensive
disorders
Any hypertensive
disorder
RR 1.3 (0.3-5.5)
Pre-existing
hypertension
RR 9.5 (2.2-41)
Eclampsia aOR 11.5 (2.8-48.6)
Pre-eclampsia aOR 1.4 (0.8-2.5)
* * Eclampsia aOR 29.1 (7.1-119)
Pre-eclampsia aOR 7.3 (4.3-
12.5)
Placenta praevia RR 10.5 (1.4-79) Praevia or abruption aOR 3.5 (2.3-
5.5)
* aOR
≠ 15.6 (2.5-
98.8)
aOR 30.4 (15.4-60)
Placental abruption RR 13.3 (1.8-100) * aOR
≠ 17.3 (1-
304.1)
aOR 8.0 (4.0-15.9)
Non-vertex at
delivery
RR 6.8 (2.4-18.8) * RR 2.4 (0.3-
19.4)
**
Chorioamnionitis No cases aOR 1.4 (0.6-3.2) * * aOR 1.6 (0.7-3.4
Polyhydramnios * aOR 3.0 (1.2-7.3) * * *
RR = Relative Risk, aOR = adjusted Odds Ratio
≠ Adjusted for age, parity, smoking status, socioeconomic status, ethnicity, BMI, multiple pregnancy, placenta praevia or abruption, labour induction and
postdates
* No data or no accurate or limited data
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argument that these studies include a number of false
positive cases. The observed association with conditions
which may form part of the differential diagnosis of
amniotic fluid embolism, for example eclampsia, also
supports this hypothesis. Conversely, the higher case
fatality observed in studies with case validation may sim-
ply indicate that these studies identify more severe cases.
Database studies without case validation may thus have
high sensitivity but conversely low positive predictive
Table 7 Associations between induction of labour and amniotic fluid embolism
Australia
(NSW)
Canada Netherlands UK US
Induction of labour
Induction of labour (all methods) * * RR 5.6 (1.5-
20.9)
aOR
≠ 3.5 (1.9-
6.7)
aOR 1.5 (0.9-
2.3)
Specific methods of induction
Any medical induction of labour RR 1.9 (0.8-4.9) aOR 1.8 (1.3-
2.7)
*
Surgical induction of labour/artificial rupture of
membranes
RR 1.4 (0.6-3.5) 1.0 (0.6-1.8) * * *
Vaginal prostaglandin (PG) E2 (induction) RR 3.4 (1.3-9.0) * * * *
Any oxytocin RR 0.8 (0.3-2.3) * * * *
Induction with both PG+oxytocin RR 2.1 (0.5.-9.1) * * * *
RR = Relative Risk, aOR = adjusted Odds Ratio
≠ Adjusted for age, parity, smoking status, socioeconomic status, ethnicity, bmi, multiple pregnancy, placenta praevia or abruption, labour induction and
postdates
* No data or no accurate or limited data
Table 8 Delivery factors associated with amniotic fluid embolism
Australia (NSW) Canada Netherlands UK US
Delivery
Mode of delivery
(baseline group normal
vaginal delivery)
caesarean section After
labour RR 48.5 (6.1-380)
Without labour RR 8.1 (0.7-
89)
caesarean section
Cephalic aOR 12.5 (7.9-
19.9)
Non-cephalic aOR 8.6 (4.3-
17.4)
caesarean section
RR 2.2 (0.5-11.1)
Cases occurring post
delivery only
caesarean section
aOR
≈ 20.3 (4.3-95.3)
caesarean section
aOR 5.7 (3.7-8.7)
instrumental
RR 36.0 (4.4-300)
Forceps aOR 5.9 (3.4-10.3)
Vacuum aOR 2.9 (1.6-5.3)
Vacuum RR 1.5
(0.2-12.3)
Forceps or vacuum
aOR
≈ 11.6 (1.7-79.8)
Forceps aOR 4.3
(1.9-7.6)
Vacuum aOR 1.9
(1.0-3.7)
vaginal breech birth
RR 151 (9.4-2400)
All cases
Caesarean section aOR
¥ 23.3 (7.8-69.7)
Forceps or vacumm
aOR
¥ 8.9 (2.0-39.5)
Manual removal of
placenta (vaginal births)
RR 19.4 (3.9-96) * * **
Macrosomia * aOR 1.6 (0.9-3.0) * OR 2.4 (0.7-8.1) *
Gestational age < 37 weeks
RR 1.9 (0.4-8.6)
37-40 weeks
1.0 (referent)
≥ 41 weeks
RR 1.7 (0.6-4.8)
> 42 weeks
aOR 1.4 (0.9-2.3)
< 37 weeks
RR 9.7 (2.3-40.8)
> 42 weeks
RR 3.2 (0.4-25.8)
≥ 41 weeks
aOR
≠ 0.4 (0.2-1)
*
RR = Relative Risk, aOR = adjusted Odds Ratio
* No data or no accurate or limited data
≈ Adjusted for age, parity, smoking status, socioeconomic status, ethnicity, bmi, placenta praevia, placenta abruption, labour induction, postdates and mode of
delivery
¥ Adjusted for age, parity, smoking status, socioeconomic status, ethnicity, bmi, multiple pregnancy, placenta praevia, placenta abruption, labour induction,
postdates and mode of delivery
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cases, whereas studies with case validation may have
lower sensitivity, due to lower case ascertainment and
false negative cases, but higher positive predictive value.
Perhaps the gold standard would be a database study
with subsequent case validation through examination of
the medical records. Such an approach, however, in the
context of a rare condition such as AFE is difficult due
to the large number of individual centres at which medi-
cal records would need to be accessed. All studies are
complicated by the additional fact that AFE is a diagno-
sis of exclusion; internationally accepted diagnostic cri-
teria for non-fatal cases do not exist, and there is a
place for development of such criteria, using as a model,
for example, the criteria used within the UK [3]. Differ-
ences in the case definitions used are likely to add to
the observed variation in incidence estimates.
Thus the optimal approach to investigating AFE may
be dependent on the purpose of the study, since each
of the practical approaches has both advantages and
disadvantages. Population-based database studies,
where suitable sources of information exist, are likely
to be the most economical option for studying the
condition; however, there is likely to be a degree of
inclusion of false positive cases, over-estimation of
incidence and thus non-uniformity of the cases exam-
ined. The use of additional criteria to exclude false
positive cases within database studies, the approach
taken in New South Wales [22], may overcome some
of these issues. However, without review of the medi-
cal records, this approach may exclude true cases that
have been poorly coded. Database studies are also lim-
ited by a restricted number of available data items;
according to the purpose of the original data collec-
tion, extremely limited information on management is
available, and temporality of events, for example in
relation to whether the AFE occurred before or after
birth, cannot be studied. For the purposes of examin-
ing risk factors and management in detail, studies with
specific prospective data collection methods may there-
fore be the best approach. Such studies are facilitated
by available collaborations designed specifically to
study rare pregnancy disorders, such as the approach
taken by UKOSS [3], the Australasian Maternity Out-
comes Surveillance System (AMOSS) and other mem-
bers of the International Network of Obstetric Survey
Systems (INOSS) [23].
Recommendation 1: Comparisons of AFE incidence
estimates should be restricted to studies using similar
methodology. Depending on the available resources and
research questions, the recommended approaches would
be either population-based database studies using addi-
tional criteria to exclude false positive cases, or tailored
data collection using existing population-based systems
Table 9 Factors associated with fatality amongst AFE cases (risk ratio (RR) unless indicated)
Condition or
procedure
Australia (NSW) Canada UK US
Age ≥ 35 years 1.1 (0.5-2.4) * aOR
≠ 2.8 (0.5-14.2) *
Multipara 1.1 (0.7-1.7) * aOR
≠ 0.9 (0.2-4.2) *
Smoked during
pregnancy
1.4 (0.3-6.5) * *
Socioeconomic status Disadvantaged (lowest
quartile)
1.4 (0.4-4.5)
* Routine, manual occupation or unemployed
aOR
≠ 1.2 (0.3-5.6)
Income $35,000+ aOR 0.3
(0.1-1.0)
Race/ethnicity Black or other ethnic minority group vs white aOR
≠
6.3 (1.1-34.9)
Previous caesarean 1.1 (0.1-9.7) * * aOR 1.1 (0.3-3.9)
Induction OR 3.5 (1.5-
8.4)
aOR
≠ 1.9 (0.4-9.2) aOR 0.7 (0.1-3.3)
Medical induction of
labour
1.6 (0.5-5.1) * *
PG+Oxytocin 2.2 (0.2-29) * * *
General anaesthesia 1.6 (0.8-2.9)
Epidural anaesthesia 2.2 (0.2-29)
Mode of delivery Forceps/vacuum 0.4 (0.1-
2.9)
CS 1.8 (0.9-3.6)
* Forceps
aOR 1.7 (0.2-14.7)
Vacuum
aOR 0.7 (0.1-5.0)
CS aOR 0.8 (0.2-2.8)
* No data or no accurate or limited data
≠ Adjusted for age, parity, socioeconomic status, ethnicity and labour induction
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conditions.
Recommendation 2: Comparisons of AFE incidence
between and within countries would be facilitated by
development of an agreed case definition, particularly
for non-fatal cases, and an agreed set of criteria to mini-
mise inclusion of false positive cases for studies con-
ducted using population-based databases.
Associated factors
We identified very little consistency among countries in
the factors associated with occurrence of AFE and no
factors consistently associated with fatality from AFE.
Maternal age appeared to be associated with the occur-
rence of AFE in all populations examined, and this may
therefore represent a true association, although the
mechanisms by which older maternal age predisposes to
AFE remain hypothetical and may include disruption of
the uterine vasculature or minor degrees of abnormal
placental invasion. The available information on placen-
tal abnormalities suggests that placenta praevia and pla-
cental abruption substantially increase (3-10 times) the
risk of AFE. Given the differing methodologies and
therefore differing biases due to potential inclusion of
f a l s ep o s i t i v ec a s e so rs e l e c t i o no fm o r es e v e r ec a s e s ,
other reported associations are very difficult to interpret.
One of the most widely reported associations, with
induction of labour, was noted to be statistically signifi-
cant in some studies (UK, Netherlands), with only cer-
tain induction methods (Australia, Canada) or the
association was not statistically significant, although the
estimated odds ratio was compatible with those reported
in most other studies (US) [2]. This illustrates the diffi-
culties of comparing data across studies with differing
case identification processes and definitions and varying
levels of detail about individual risk factors.
With other factors, such as mode of delivery, issues
concerning the timing of the event make the data diffi-
cult to interpret. The data we examined were often lim-
ited, frequently because the timing of the AFE in
relation to the delivery was not available, and hence we
were unable to identify cases in which a caesarean or
operative vaginal delivery was a cause and not a conse-
quence of the AFE. In the studies where timing was
available, small numbers of women in certain subgroups,
for example the number of cases undergoing operative
vaginal delivery, limited statistical power. It is important
to note, however, in the context of rising caesarean
delivery rates worldwide, that there was a significant
association with caesarean delivery in the one country
( U K )i nw h i c hw ew e r ea b l et oi n v e s t i g a t es p e c i f i c a l l y
cases where the AFE occurred after delivery. Analysis of
pooled international data, obtained using consistent
methodologies with agreed definitions and case
validation, would provide more reliable information on
these associated factors and hence provide the potential
to develop appropriate preventive strategies which
would otherwise be limited.
Recommendation 3: Groups conducting detailed
population-based studies on AFE should develop an
agreed strategy to allow combined analysis of data
obtained using consistent methodologies in order to
identify potentially modifiable risk factors.
Outcomes
There were no clear differences in maternal mortality
ratios due to AFE between countries or by study metho-
dology. Information on other outcomes for women was
very limited, although data on cerebral injury [3] suggest
that AFE may have a significant impact in the long term
outcomes of survivors, and this requires further investi-
gation. None of the data sets included information on
long-term maternal outcome after non-fatal AFE. Data
on infant outcomes were only available for sources
which can link data on the mother and infant or from
studies which collect specific data. Although limited, the
available data suggest the perinatal death rate associated
with AFE is high (7-38%). Similarly, we were unable to
investigate any potential relationship between manage-
ment and outcomes because of extremely limited data.
Further international collaborative studies using specific
data collection would allow for more detailed investiga-
tion of the outcomes for mother and infant, over both
short and longer term, and any relationship with
management.
Recommendation 4: Future specific studies on AFE
should aim to collect information on management and
longer-term outcomes for both mothers and infants in
order to guide best practice, counselling and service
planning.
Strengths and limitations of this analysis
This analysis used data from five high resource coun-
tries, and the results are thus generalizable only to
countries with similar resource settings. As discussed
above, data on AFE were obtained using different study
methodologies, and therefore this limits the comparabil-
ity of some of the results. AFE is a rare condition, and
all studies have limited power to detect true associations
as statistically significant. We hope that this may be
addressed in the future by further international colla-
borative studies, an approach that we would advocate
for research into all rare conditions in pregnancy.
Conclusions
This analysis has highlighted the benefits of detailed
comparison of AFE incidence and ascertainment meth-
o d sf r o md i f f e r e n tp o p u l a t i o n - b a s e ds t u d i e sa n dh a s
Knight et al. BMC Pregnancy and Childbirth 2012, 12:7
http://www.biomedcentral.com/1471-2393/12/7
Page 9 of 11identified a number of difficulties with making direct
international comparisons. The study methodology
impacts on estimates of disease incidence and case fatal-
ity, and may also account for inconsistencies in reported
risk factors. There is a need for consistent study meth-
odologies, including agreed case definition and case vali-
dation criteria. The use of such unified methodologies
will allow for valid international comparisons of inci-
dence in the future, and may permit pooling of interna-
tional data to provide more reliable information on
associated factors, management and outcomes, thus
allowing for development of preventive and treatment
strategies to improve outcomes of this rare but serious
condition.
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